8.17

1.11% 0.09

Kyverna Therapeutics Inc (KYTX)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$8.08

Aprire:

$8.1

Volume 24 ore:

579.85K

Relative Volume:

0.57

Capitalizzazione di mercato:

$505.26M

Reddito:

Utile/perdita netta:

$-156.40M

Rapporto P/E:

-2.4909

EPS:

-3.2799

Flusso di cassa netto:

$-151.53M

1 W Prestazione:

+2.64%

1M Prestazione:

+2.90%

6M Prestazione:

+12.53%

1 anno Prestazione:

+130.79%

Intervallo 1D:

$7.80

$8.29

Intervallo di 1 settimana:

$7.78

$8.6647

Portata 52W:

$3.27

$13.67

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Nome

Kyverna Therapeutics Inc

Settore

Healthcare (1080)

Industria

Biotechnology (604)

Telefono

(510) 626-8331

Indirizzo

5980 HORTON STREET, EMERYVILLE

Dipendente

129

Cinguettio

Prossima data di guadagno

2026-08-11

Ultimi documenti SEC

KYTX's Discussions on Twitter

Compare KYTX vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KYTX Kyverna Therapeutics Inc	8.17	497.84M	0	-156.40M	-151.53M	-3.2799
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-20	Iniziato	William Blair	Outperform
2025-05-27	Aggiornamento	H.C. Wainwright	Neutral → Buy
2024-10-10	Iniziato	UBS	Buy
2024-10-09	Iniziato	Rodman & Renshaw	Buy
2024-07-03	Iniziato	H.C. Wainwright	Neutral
2024-03-04	Iniziato	JP Morgan	Overweight
2024-03-04	Iniziato	Leerink Partners	Outperform
2024-03-04	Iniziato	Morgan Stanley	Overweight
2024-03-04	Iniziato	Wells Fargo	Overweight

Mostra tutto

Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie

Aug 14, 2026

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat

Aug 14, 2026

Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan

Aug 14, 2026

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 14, 2026

Aug 13, 2026

KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits

Aug 13, 2026

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha

Aug 13, 2026

Aug 12, 2026

H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Aug 12, 2026

Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat

Aug 12, 2026

Aug 11, 2026

Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Aug 11, 2026

Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade

Aug 11, 2026

Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2026

Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media

Aug 11, 2026

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times

Aug 11, 2026

KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView

Aug 11, 2026

Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan

Aug 11, 2026

FDA designation puts Kyverna’s one-dose cell therapy in focus for progressive MS - Stock Titan

Aug 11, 2026

Aug 09, 2026

Renaissance Technologies LLC Grows Stock Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat

Aug 09, 2026

Aug 07, 2026

Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a shareEarnings Preview - TradingView

Aug 07, 2026